Sanofi

Sanofi sees midphase success in multiple sclerosis decades after safety concerns scuttled peers
Sanofi sees midphase success in multiple sclerosis decades after safety concerns scuttled peers
Fierce Biotech
Sanofi
MS
multiple sclerosis
clinical trials
frexalimab
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Sanofi, Regeneron flesh out COPD data with Dupixent
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Sanofi
Regeneron
COPD
Dupixent
Flag link:
Supreme Court rules against Amgen bid to revive cholesterol drug patents
Supreme Court rules against Amgen bid to revive cholesterol drug patents
KFGO/Reuters
Supreme Court
Amgen
Sanofi
Regeneron
patents
Repatha
legal
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm
Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm
BioSpace
Sanofi
AstraZeneca
RSV
antibodies
infants
clinical trials
Flag link:
What you need to know about pharma, PBM execs testifying on insulin prices
What you need to know about pharma, PBM execs testifying on insulin prices
Medical Marketing and Media
PBMs
insulin
diabetes
drug pricing
Sanofi
Novo Nordisk
Eli Lilly
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
BioSpace
Biogen
Novartis
Sanofi
earnings
R&D
Flag link:
Chronic hives: Four major clinical trials to watch in 2023
Chronic hives: Four major clinical trials to watch in 2023
Clinical Trials Arena
chronic hives
chronic urticaria
clinical trials
Sanofi
Regeneron
dupilumab
Amgen
tezepelumab
Allakos
lirentelimab
Celldex Therapeutics
barzolvolimab
Flag link:
Flatiron and Sanofi partner to streamline clinical trial data acquisition
Flatiron and Sanofi partner to streamline clinical trial data acquisition
Clinical Trials Arena
Flatiron Health
Sanofi
clinical trials
Flag link:
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
BioPharma Dive
Maze Therapeutics
Pompe disease
Sanofi
MZE001
Flag link:
Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds
Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds
Fierce Biotech
Sanofi
M&A
earnings
Ablynx
Principia Biopharma
Flag link:
ALX and Sanofi partner to start Phase l/ll trial of RRMM combo therapy
ALX and Sanofi partner to start Phase l/ll trial of RRMM combo therapy
Clinical Trials Arena
ALX Oncology
Sanofi
clinical trials
evorpacept
Sarclisa
relapsed or refractory multiple myeloma
Flag link:
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
BioPharma Dive
Amgen
Regeneron Pharmaceuticals
Sanofi
Supreme Court
patents
Pfizer
Bayer
Roche
Genentech
AstraZeneca
JNJ
Flag link:
What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her take
What spurred Lilly, Novo and Sanofi to slash insulin prices? Expert gives her take
Fierce Pharma
Novo Nordisk
Eli Lilly
Sanofi
insulin
diabetes
drug prices
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma’s biggest spenders revealed: 2022 edition
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Flag link:
AACR 2023 – Hippo makes a splash
AACR 2023 – Hippo makes a splash
EP Vantage
Vivace Therapeutics
VT3989
AACR
Novartis
Sanofi
Ikena Oncology
Flag link:
Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi
Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi
Fierce Pharma
legal
Supreme Court
Novartis
Gilenya
Sanofi
Viatris
EpiPens
Flag link:

Pages